Cel Sci (CVM) Short term Debt (2010 - 2018)

Cel Sci (CVM) posted Short term Debt of $1.2 million for Q1 2018, up 34.54% sequentially from $874593.0 in Q4 2017.

Cel Sci (CVM) Short term Debt (2010 - 2018) Analysis & Trends

Cel Sci has reported Short term Debt for 7 years, with the latest figure at $1.2 million in Q1 2018.

Quarterly Short term Debt changed N/A year-over-year to $1.2 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $1.2 million (changed N/A YoY) and the FY2017 annual result came in at $994258.0, changed N/A from the prior year.
Short term Debt grew to $1.2 million in Q1 2018 per CVM's latest filing, from $874593.0 in the prior quarter.
Over five years, Short term Debt peaked at $1.2 million in Q1 2018 and troughed at $325794.0 in Q2 2017.
A 3-year average of $895072.4 and a median of $994258.0 in 2017 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.71 Bn	130.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.60 Bn	77.60 Bn	3.93 Bn
3	Argenx Se	64.82 Bn	59.63 Bn	1.37 Bn
4	Moderna	57.92 Bn	52.79 Bn	52.00 Mn
5	BeOne Medicines	41.88 Bn	36.78 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.46 Bn	28.15 Bn	992.69 Mn
7	BioNTech SE	27.96 Bn	9.57 Bn	668.28 Mn
8	Insmed	27.35 Bn	26.19 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cel Sci	2.12 Mn	-4.42 Mn	-

Download Data